StreetAlpha.app
Home › Stocks › LENZ

LENZ Therapeutics, Inc. (LENZ)

Healthcare
$2.96
▼ −11.23%
LAST CLOSE · NOV 20

LENZ Therapeutics sells VIZZ, a daily eye drop that improves near vision for adults with presbyopia. It last closed at $2.96 on Nov 20, down 11.23% on the day. The next earnings report for LENZ is expected around Tue, Mar 23, 2027. For the quarter ended Sep 2026, LENZ reported EPS of -$0.99 on revenue of $3.4M, with revenue down 72.9% from a year ago. Over its last 8 reports the stock moved an average of 10.7% the session after earnings. Over the last 12 months LENZ insiders bought $366K of stock on the open market and sold $9.1M, according to SEC Form 4 filings.

AI Auto Pilots
Is LENZ in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold LENZ.

Key Stats

Last 12 months
Results
Revenue
$12.4M
−29.4% vs a year ago
Net income
−$140.3M
−1135.0% margin
EPS (diluted)
−$4.53
Free cash flow
−$127.7M
−1033.3% margin
Valuation
Market cap
$93.2M
31.4M shares
P/E
–
No P/E while losing money
Price to sales
7.5
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$30.6M
At Sep 30
Shareholder equity
$192.0M
Shares outstanding
31.4M
At Oct 28
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2024: $0$0FY2024FY2025: $19.1M$19.1MFY2025

From LENZ's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 3). Last 12 months adds up the four latest quarters.

Next report
Mar 23
Estimated date · Time not announced
Reported EPS
-$0.99
Quarter ended Sep 2026
Year ago EPS
-$0.59
Same quarter last year
Revenue
$3.4M
−72.9% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$0.41Dec '24Mar 2025: -$0.53Mar '25Jun 2025: -$0.53Jun '25Sep 2025: -$0.59Sep '25Dec 2025: -$1.20Dec '25Mar 2026: -$1.32Mar '26Jun 2026: -$1.02Jun '26Sep 2026: -$0.99Sep '26Latest -$0.99
Revenue by quarter
Dec 2024: $0Dec '24Mar 2025: $0Mar '25Jun 2025: $5.0MJun '25Sep 2025: $12.5MSep '25Dec 2025: $1.6MDec '25Mar 2026: $1.9MMar '26Jun 2026: $5.5MJun '26Sep 2026: $3.4MSep '26Latest $3.4M
How LENZ moved after its last 8 reports
Average move the session after a report ±10.7%
Oct 28, 2026After the close+8.7%
Aug 11, 2026After the close−3.3%
May 11, 2026After the close−20.8%
Mar 24, 2026Time not announced−17.9%
Jan 7, 2026After the close−6.6%
Nov 5, 2025Time not announced−23.5%
Jul 30, 2025Time not announced−2.9%
May 7, 2025After the close+2.1%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on LENZStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on LENZ
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on LENZ

Technical Analysis

LENZ · as of the Nov 20 close · updated each morning
Downtrend

The stock is 18% below its 20 day and 22% below its 50 day average. It is 134% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 39). The nearest support is the 52 week low at $2.80, and the nearest resistance the Pivot at $3.08.

Short trendBearish
Long trendBearish
MomentumWeak
StretchNormal
VolatilityHigh, 12.3%/day
Key levels
$32.1352 week high+985.5%
$6.94200 day average+134.5%
$4.42100 day average+49.3%
$3.73Swing high (Nov 3)+26.0%
$3.6350 day average+22.6%
$3.5120 day average+18.6%
$3.33Pivot R1+12.5%
$3.08Pivot+4.1%
$2.96Last close
$2.8052 week low−5.4%
$2.80Swing low (Nov 2)−5.4%
$2.71Pivot S1−8.4%
Indicators
RSI (14)39.17Weak, oversold below 30Neutral
MACD-0.06Below its signal lineBearish
Stochastic23.3Middle of its rangeNeutral
ADX (14)21.7Weak trend
Williams %R-90.7Oversold below −80, overbought above −20Oversold
CCI (20)-83.4Oversold below −100, overbought above 100Neutral
Rate of change−15.3%Change over 10 sessionsBearish
ATR (14)$0.36Typical daily range, 12.3% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for LENZ

What happened before

See how LENZ did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow LENZ usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How LENZ has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for LENZHow many large options trades hit LENZ, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

LENZ Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bearish
Strongly bearishNeutralStrongly bullish
  • ●68 buying vs 66 selling
  • ▼Held by funds -13.1 pts
  • ▼Funds holding -7
  • ▼Superinvestors: 1 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding138145−4.8%
In funds' top 10330.0%
Held by funds97.4%110.5%−13.1 pts
New / increased18 / 5028 / 59−21.8%
Reduced / sold out39 / 2734 / 27+8.2%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See LENZ institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

LENZ Insider Trading

All filings →
Insider trading · 12 months
Insiders are net sellers
Bought$366K3 buys · 3 insiders
Sold$9.1M1 sale · 1 insider
Cluster buy: 3 insiders bought $366K between Mar 27 and Mar 27.
2026-03 bought $366K2026-10 sold $9.1MDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Oct 29Ra Capital Management, L.P.10% ownerSale2,718,684$3.36$9.1M
Mar 27Daniel R. ChevallardCFOBuy7,500$8.57$64K
Mar 27Evert B. SchimmelpenninkPresident, CEO and SecretaryBuy28,089$8.95$251K
Mar 27Jeffrey P. GeorgeDirectorBuy5,592$8.92$50K
Nov 17, 2025Shawn OlssonChief Commercial OfficerSale plan10,000$26.10$261K
Nov 7, 2025James W MccollumDirectorBuy10,500$22.79$239K
Every insider buy and sale for LENZ over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See LENZ insider trades →

From SEC Form 4 filings by LENZ's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether LENZ is in one of them and how their past LENZ trades turned out.

LENZ in the AI portfolios
Loading…

LENZ News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered LENZ in an article yet. Here's the latest on the wider market.

LENZ in the news

About LENZ Therapeutics

LENZ Therapeutics is a pharmaceutical company based in Solana Beach, California, that develops and sells treatments for eye conditions. Its main product is VIZZ, a daily eye drop that improves near vision for adults with presbyopia, the loss of close-up focus that comes with aging. The company sells VIZZ in the United States to eye care professionals such as optometrists and ophthalmologists, and to patients who buy it at retail pharmacies.

Headquarters
Solana Beach, CA